-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Unity Biotechnology, Maintains $4 Price Target

Benzinga·04/23/2025 12:20:55
Listen to the news
Chardan Capital analyst Daniil Gataulin maintains Unity Biotechnology (NASDAQ:UBX) with a Buy and maintains $4 price target.